Plasma cell myeloma.
Plasma cell myeloma is a heterogenous disease with variable clinical presentation and outcome. The prognosis is largely determined by tumor biology. Newer therapeutic agents are rapidly changing the survival outlook of myeloma patients.
Lin
Pei
P
Department of Hematopathology, University of Texas-MD Anderson Cancer Center, Houston, TX 77070, USA. peilin@mdanderson.org
D019938:Cyclin D1 / Q000235:genetics; D005434:Flow Cytometry; D011495:Histone-Lysine N-Methyltransferase / Q000235:genetics; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D016130:Immunophenotyping; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000235:genetics* / Q000276:immunology; D011379:Prognosis; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000235:genetics; D012097:Repressor Proteins / Q000235:genetics; D014178:Translocation, Genetic
C530104:CCND1 protein, human; D007143:Immunoglobulin Heavy Chains; D012097:Repressor Proteins; D019938:Cyclin D1; D011495:Histone-Lysine N-Methyltransferase; C419586:NSD2 protein, human; C496365:FGFR3 protein, human; D051498:Receptor, Fibroblast Growth Factor, Type 3